Psychedelic Science Research,
what lands in your inbox each week:
- 📚7 fresh studies
- 📝plain-language summaries
- ✅direct links to original studies
- 🏅top journal indicators
- 📅weekly delivery
- 🧘♂️always free
some of our latest newsletters:
(select one to read it below)
Psychedelics disrupt brain signal flow in both humans and mice across LSD, psilocybin, and MDMA
Psychedelic research is moving fast—from understanding how these compounds rewire the brain to testing them for everything from depression to ADHD. This week brought fresh insights on brain mechanisms, real-world implementation challenges, and some surprising findings about who's actually getting these treatments.
🧠 Psychedelics disrupt brain's "bottom-up" information flow across species
- Researchers tracked brain activity patterns in both humans and mice during psychedelic experiences, analyzing data from 9 drug-vs-control studies using LSD, psilocybin, and MDMA
- All psychedelics reduced the magnitude and "bottom-up" direction of signal flow within the brain's default mode network (the regions active during rest and self-reflection)
- This disruption of normal hierarchical brain processing was uniquely linked to the subjective effects people reported—not just general brain changes
Why it matters: This provides a unified explanation for how different psychedelics alter consciousness, suggesting they all work by disrupting the brain's normal information processing hierarchy rather than just changing overall activity levels.
Key Findings
🏥 Psilocybin therapy hits real-world roadblocks despite approval
- A Canadian cancer center received regulatory approval for psilocybin-assisted therapy but treated zero patients in the first year
- Despite estimated costs of only $2,648-5,827 CAD per patient, administrative procedures and unclear referral processes created major barriers
- Staff viewed the treatment favorably but emphasized the need to align it with existing care pathways
💊 Most people with alcohol problems are open to psychedelic therapy
- 64.3% of 112 people with alcohol use disorder said they'd be willing to try psychedelic therapy in a clinical trial
- 62.5% were already aware of psychedelic research for mental health conditions
- Willingness was strongly linked to expectations of success (3.3x higher odds) but not to age or general knowledge about psychedelics
🔍 Ketamine clinics advertising home use often lack medical doctors
- 233 ketamine clinics in the New York area were identified through web searches, with 36.5% advertising at-home ketamine use
- Only 51.5% of all clinics listed a medical doctor on their team, and clinics advertising home use were less likely to have MDs (54% less likely)
- 42.9% advertised oral ketamine, and oral ketamine clinics were 4x more likely to offer at-home treatment
⚠️ Psychedelic-psychosis link may be misleading
- Among 273,466 people with substance-related hospital admissions, 16.4% of hallucinogen users later had psychosis diagnoses vs 6.6% of other substance users
- However, when researchers adjusted for pre-existing psychiatric conditions, the increased psychosis risk disappeared entirely
- The apparent hallucinogen-psychosis connection was explained by underlying mental health vulnerabilities, not the drugs themselves
🎯 Personality predicts which psychedelic effects you'll experience
- 426 psychedelic users completed personality tests and rated the intensity of 20 different sensory distortions during their experiences
- Specific personality traits correlated with particular effects: visual trails, "breathing" objects, out-of-body experiences, and synesthesia all linked to measurable personality differences
- The associations held even when controlling for dose, setting, and demographics, though the effects were moderate
❌ Psychedelics show no clear benefit for ADHD in systematic review
- Only 6 studies met criteria for examining psychedelics as ADHD treatment: 1 randomized trial found no significant difference vs placebo, 3 surveys reported positive effects, 1 measured improvement, and 1 case study with ketamine
- The single rigorous randomized controlled trial showed no statistically important improvement compared to placebo
- Researchers concluded there's insufficient evidence to recommend psychedelic use for ADHD
Implications
The field is revealing both the promise and complexity of psychedelic medicine. While the brain mechanisms are becoming clearer and patient interest is high, real-world implementation faces significant hurdles, and some hoped-for applications may not pan out. The disconnect between regulatory approval and actual patient access suggests the next phase of psychedelic medicine will be as much about healthcare delivery as scientific discovery.
Science is the only real news.
The rest is just drama 📰
And nowadays, we see that drama everywhere.
Drama sells ads, ads sell products, and my attention sells to the highest bidder.
Drama media is junk food for the mind.
A quick rush, hard to avoid, but little nutritional value.
The brain wants broccoli 🧠🥦
And look, it's not that science never makes the news.
But think about when it does—does the news really understand the science it reports on?
Like it or not, AI exists now.
And it happens to be a huge science nerd… 🔭🤖
…with a superpower…
...unlike an average science nerd, AI can explain it simply.
I built OpenScience to make the constant stream of new studies accessible to anyone.
To free science from academic jargon and tiny-fonted PDFs.
OpenScience is a weekly newsletter of 7 compelling studies from the past week in the topic of your choice.
Made simple, digestible, and delightful by AI.
Interested in CRISPR?
The latest Long Covid research?
Psychedelic medicine?
Follow the actual science, as it comes out.
Every study is linked to the original PubMed so you can verify the AI's summary yourself.
Pick a topic, get the weekly email, and give your mind the broccoli it deserves 🥦
The real-time unfolding of science is too interesting not to follow.